1. ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial
- Author
-
Zilli, Thomas; https://orcid.org/0000-0002-4784-9883, Franzese, Ciro; https://orcid.org/0000-0001-6893-6284, Guckenberger, Matthias; https://orcid.org/0000-0002-7146-9071, Giaj-Levra, Niccolò, Mach, Nicolas; https://orcid.org/0000-0001-8944-1088, Koutsouvelis, Nikolaos; https://orcid.org/0000-0002-9343-8540, Achard, Vérane; https://orcid.org/0000-0002-5374-8851, Mcdonald, Andrew, Alongi, Filippo, Scorsetti, Marta, Constantin, Guillaume, Bertaut, Aurelie; https://orcid.org/0000-0002-7934-9509, Miralbell, Raymond, Zilli, Thomas; https://orcid.org/0000-0002-4784-9883, Franzese, Ciro; https://orcid.org/0000-0001-6893-6284, Guckenberger, Matthias; https://orcid.org/0000-0002-7146-9071, Giaj-Levra, Niccolò, Mach, Nicolas; https://orcid.org/0000-0001-8944-1088, Koutsouvelis, Nikolaos; https://orcid.org/0000-0002-9343-8540, Achard, Vérane; https://orcid.org/0000-0002-5374-8851, Mcdonald, Andrew, Alongi, Filippo, Scorsetti, Marta, Constantin, Guillaume, Bertaut, Aurelie; https://orcid.org/0000-0002-7934-9509, and Miralbell, Raymond
- Abstract
PURPOSE To assess in a prospective, multicenter, single-arm phase I/II study the early safety and efficacy profile of single fraction urethra-sparing stereotactic body radiotherapy (SBRT) for men with localized prostate cancer. MATERIAL AND METHODS Patients with low- and intermediate-risk localized prostate cancer without significant tumor in the transitional zone were recruited. A single-fraction of 19 Gy was delivered to the prostate, with 17 Gy dose-reduction to the urethra. Intrafraction motion was monitored using intraprostatic electromagnetic transponders with intra-fraction correction of displacements exceeding 3 mm. Genitourinary (GU), gastrointestinal (GI), and sexual toxicity during the first 18 months were evaluated using the CTCAE v4.0 grading scale. Quality of life was assessed using the International Prostate Symptom Score, the Expanded Prostate Cancer Index composite 26 score, and the International Index of Erectile Function score. RESULTS Among the 45 patients recruited in 5 centers between 2017 and 2022, 43 received the single fraction without protocol deviations, and 34 had a minimal follow-up of 18 months. The worst GU toxicity was observed at day-5 after SBRT (42.5 % and 20 % with grade 1 and 2, respectively), returning to baseline at week-12 and month-6 (<3% with grade 2), with a 12 % grade 2 flare at month 18. Gl toxicity was mild in the acute phase, with no grade ≥ 2 events (12 % grade 1 at month 6). Grade-3 proctitis was observed in one patient at month 12, with < 3 % grade 2 toxicity at month 18. Mean GU and GI bother scores showed a decline at day 5, a complete recovery at month 6, and a flare between month 12 and 18. Mean PSA dropped from 6.2 ng/ml to 1.2 ng/ml at month 18 and 0.7 ng/ml at month 24. After a median follow-up time of 26 months, 3 biochemical failures (7 %) were observed at month 17, 21 and 30. CONCLUSIONS In this multicenter phase I/II trial, we demonstrated that a 19 Gy single-fraction urethra-sparing SBRT is feasible and a
- Published
- 2024